

[SJIF 2020: 6.224](#)
[IFS 2020 4.085](#)

Cellular basic of carcinogenesis (Review)

Madaminov Akhmad^a, Khatamov Shuhrat^a, Abdurakhmonov Otabek^a, Khudayorov Murod^b

^aNational Cancer Research Center of Uzbekistan, Department of Head and Neck Surgery

^bTashkent Medical Academy, Department of Oncology

Introduction

The human body is made up of cells that combine all the features of life controlled by a complex system, and important biological processes take place between various factors in the external environment. A cell is a functional unit that provides the transmission of genetic information, metabolism, energy exchange, and the integrity of life. Single-celled individuals found in nature have the property of living autonomously and consist of a single cell with a very simple structure. Cancer cells may also resemble amoebae in some physiological aspects, such as simplicity of differentiation, lack of definitive form, dynamic activity of cytoplasm, high demand for trophic and plastic primary substrates. The presence of these specific features is also reflected in the appearance of the cell (Fig. 1). Why do cancer cells live independently of the system that controls the vital activity of the human body, multiply non-stop rapidly, and are more viable than healthy cells? According to historical sources, around 400 BC, the ancient Greek scientist Hippocrates identified a disease that resembled a crab that develops from a disruption of the circulatory system of black bile in the human body and moves in different directions). Abu Ali ibn Sina (980-1037) stated the following about the development of cancer: "Not all causes affect the body, and no cause can cause disease without the body's sensitivity"²⁸. In 1931, the German physiologist Otto Heinrich Warburg supported the hypothesis that the energy expended in the growth of cancer cells was formed mainly as a result of anaerobic breakdown of glucose (glucose fermentation). This differs from healthy cells in that pyruvic acid is formed as a result of glucose oxidation in mitochondria. This means that cancer is an evolutionary ancient disease, and along with the civilization of life, this disease is also on the rise. At a time when almost a quarter of the 21st century is passing and innovative technologies are being widely used in medicine, what has been achieved by humanity in this regard. Nowadays, finding a gene in cancer, finding a target for that gene is a bright sign that a new era has arrived in modern oncology¹. Many scientific literatures contain various research findings or hypotheses about the causes of cancer and the mechanisms that affect them, but many questions on this topic still remain unclear. Genetic instability, which is the

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

main cause of cancer heterogeneity, persistent disruption of the sequence of DNA nucleotides sequences, and chromosome rearrangement pose significant obstacles to the development of more effective treatments.




Figure 1. Cytoplasmic growths in amoeba (a) and cancer (b) cells

Genetics and epigenetics

In 2003, the Human Genome Research Project completed many years of research by scientists from around the world to decipher the structure of the human genome, which is made up of deoxyribonucleic acid (DNA) molecules, and identified between 20,000 and 25,000 genes⁶⁴. The human genome is made up of about three billion DNA base pairs that make up all the chromosomes. Base pairs (bp) are the hydrogen compounds of adenine-thymine and guanine-cytosine in the DNA helix⁷¹. Genome units of measurement: one million nucleotide base pairs (bp) equal to 1 Mb (mega base), 978 Mb equal to 1 pictogram (pictogram = $1 * 10^{-12}$ grams). Relevant genes are responsible for cell growth, differentiation, proliferation, viability, programmed death (apoptosis), response to external factors, and other important life activities, and information is transmitted through ribonucleic acid (RNA) and proteins²¹. Suppression, repression, and regulation of encoded genes are controlled using the epigenome (epigenetics). Epigenetics is a relatively new field that has not yet been as widely studied as genetics, which is understood as a branch of genetics that studies the hereditary changes in gene activity during organism development or cell division. It is estimated that 5% of human cancers are caused by viruses, 5% by radiation, and the remaining 90% by chemicals¹⁵. About 30% of them are due to the use of tobacco products, the rest are related to nutrition, lifestyle and environment. All chemical carcinogens or their derivatives are highly reactive electrophiles (donor-acceptor mechanism) with electron (e^-) deficient atoms that can easily react with electron-rich nucleophiles in the cell. DNA, in particular, consists of many nucleophilic centers (NH_2 -groups) in which DNA-damaging substances can form appendages

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

(DNA-adducts) through one or more covalent bonds. With the advent of new technologies in molecular analysis, gene expression profiling, gene network, microRNA, gene discovery and pathway analysis, integrated transcriptome collection, and two genetic carcinogenesis using ChIP-Seq (chromatin immunoprecipitation sequencing, cysstrom) has been shown to be more complex than clone evolution^{5,52}. The modern multi-stage model of carcinogenesis involves at least 80 mutations or changes in the cancer gene, about a dozen of which are “drivers” of cancer development processes. The process of carcinogenesis can occur due to changes in four categories of genes, namely, activation of oncogenes, inactivation of suppressor genes, annulation of apoptosis and DNA repair genes^{36,81}.

The development of multi-stage carcinogenesis at each stage of cell proliferation (initiation, stimulation, progression) is inextricably linked with the mechanism of positive or negative interaction of oncogenes, suppressor genes, growth factors and their associated receptors⁷¹. The prevalent model of the cell cycle consists of a series of transitions, and at some control points the restriction criteria under the influence of control factors must be followed before the cell moves to the next stage⁵⁷. The cell cycle consists of S (DNA synthesis) and M (mitosis) phases, separated by two disruption phases (G1 and G2)⁵¹. It is tightly controlled by a group of heterodimeric protein kinases, including cyclin and cyclin-dependent kinases (Cdk), which regulate the progression of the cell cycle and contain catalytic subunits⁴⁰. There are many combinations of cyclin-dependent kinase complexes and are characterized by the expression and activity of patterns at each stage of the cell cycle²⁷. According to scientific data, more than fifteen classes of cyclins are described (including A, B, C, D, E, F, H, K, L, T, and Y), whose function is to control and repair DNA synthesis from cell cycle control, transcription, proteolysis, up to RNA splicing and cell differentiation³². Specific cycles predominate in the movement of each cell cycle, for example, cyclin D in phase G1, cyclins E and A in phase S, and cyclins A and B in phase G2 / M. The peak of synthesis and activity of cyclins D and E regulates the transition from phase G1 to phase S. Cyclins A and B manifest themselves at the maximum level of exposure at the end of the cycle and are considered regulators of the transition from G2 to mitosis. When cyclins rise to maximum activity according to the phase of the cell cycle, they lead to phosphorylation of various specific-target molecules (cyclin-dependent kinases). These events occur in a strictly regulated time sequence supported by consistent restriction points. The presence of control components at these restriction points allows DNA repair by slowing down the process before moving on to the next cycle. Replication of a damaged genetic

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

pattern will undoubtedly lead to irreversible chromosome aberrations and high-level mutations^{22,27,57}. The two main restriction points are particularly important after DNA damage and are established in phases G1 (before DNA replication) and G2 (before chromosome segregation) (Figure 2). Loss of the G1 restriction point causes genome instability during the interaction of unrecoverable DNA with the DNA replication mechanism, leading to deletion-type mutations and aberrant gene amplification⁴⁷. Inactivation of the G1 restriction point serves as an initial stage, prone to unregulated cell growth (initiation), increasing the likelihood of subsequent genetic changes and creating a fully developed neoplastic phenotype. Control at the G1 restriction point depends on the D1 cyclin (transition phase from G1 to S) and the E cyclin (mid-phase S). Hyperexpression of D1 or E cyclin and subsequent activation of D1 cyclin and E cyclin/ Cdk complexes lead to phase C transition and shortening of G1 time^{47,51,57,73}. Cyclin D1 hyperexpression is observed in many dangerous human cancers, including breast and lung small cell carcinomas, sarcomas, melanoma, V-cell lymphomas, and head-neck squamous cell carcinomas. The cyclin D1 / Cdk4 complex is involved in the phosphorylation of pRB, a gene product responsible for retinoblastoma⁶⁰. The pRB protein acts as a negative regulator of the expression of certain genes by forming a complex with DNA-binding proteins belonging to the E2F family¹⁶. In the G0 phase of the cell (where division has stopped), low-phosphorylated pRB binds to proteins belonging to the E2F group, leading to E2F-mediated transcriptional repression. High phosphorylation of pRB protein under the influence of cyclin / Cdk complexes leads to dissociation of E2F protein and transcription of genes that in turn help to enter the S phase⁵⁷. Thus, insufficient phosphorylation of pRB keeps cells in G1 (or G0), while phosphorylation inactivates pRB and allows it to exit G1. pRB inactivation is most commonly seen in retinoblastoma, osteosarcoma, carcinoid tumors, and non-small cell lung cancer⁵⁴.

In addition to cyclin and cyclin / Cdk complexes, the p53 gene suppressor is also essential to maintain the G1 phase after DNA damage. A mutation in the p53 locus is the most common genetic change associated with cancer. The p53 protein can be divided into three main components: the transactivation amino-terminal domain, the site-specific hyperreactive central part of the DNA sequence, and the multifunctional carboxy-terminal domains (tetramerization). Many p53 mutations involve highly conservative segments of the DNA-specific central part. Inactivation of p53 allows the synthesis of damaged DNA and increases the frequency of some types of mutations^{47,48,71}. This high frequency has been observed as a result of various mechanisms of DNA damage, such as

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

ionizing radiation (helix rupture), alkylation with methyl methanesulfonate, ultraviolet radiation (photodimers), and various environmental carcinogens. One of the key roles of p53 is to ensure that cell growth stops in G1 in response to genotoxic damage and recovers before DNA replication. The natural type p53 (wild type) is usually kept stable at very low concentrations due to the shortness of the half-life (half-decomposition)⁴⁸. However, it stabilizes and accumulates in cells that have undergone DNA damage or respond to certain forms of stress. After DNA damage, p53 binds to specific consensus components, activating the transcription of several genes of the lower order. One of these genes encodes the p21 protein²⁰. The p21 gene belongs to the family of negative regulators of the cell cycle, which act as molecules that inhibit cycle-related kinases. The genes encoding these proteins are called CKI (Cdk inhibitor, CKI, CDI, CDKI) genes. These negative regulators form stable complexes with cyclin / Cdk units and inactivate them. The p21 cycle inactivates the E-Cdk2, cyclin A-Cdk2, and cyclin D1-, D2-, and D3-Cdk4 complexes, thereby inhibiting the phosphorylation of pRB and preventing the cell cycle from exiting G1⁵³. The p53 protein also activates the VAX (Bcl-2 - Associated X protein) gene, which is involved in regulating apoptosis. Apoptosis is the mechanism by which cells stop the life cycle, leading to “programmed death”. Apoptotic cells contract in response to DNA damage and chromosome condensation. These changes prevent the replication of genetically damaged cells to an irreversible extent. During the mitotic phase, chromatin must be evenly distributed to the daughter cells, but DNA replication must be completed before segregation occurs and all damaged parts of the DNA must be restored. If mitosis occurs when DNA is damaged or during replication, it can lead to genome fragmentation and loss of genetic material⁴⁶. Genome stability is controlled by a large network of proteins called DNA damage response (DDR), which detects DNA damage and facilitates repair. Activation of DDR proteins leads to activation of transducer kinases CHK1 and CHK2 and other effector proteins. DDR can respond to DNA damage by disrupting phases G1, S, or G2^{57,73}.

[SJIF 2020: 6.224](#)
[IFS 2020 4.085](#)




Figure 2. Control of the cell cycle (- restriction points).

The p53 protein controls its work by activating the MDM2 gene. The product encoded by MDM2 is a “zinc finger” protein (mdm2) that contains the p53 site-specific binding component. The mdm2 protein binds to p53 and acts as a negative regulator, inhibiting the transcriptional activity of the natural type p53 and forming a feedback autoregulation ring. The presence of a carboxyl-terminal domain of mdm2, which binds site-specific to the pRB and limits its function, has been identified. Similar to the hyperexpression of mdm2, some virus oncoprotein products inactivate both p53 and pRB and exhibit a potential relationship between p53 and pRB in cell cycle management, apoptosis, and tumor development⁴⁸. The cell cycle and its regulatory proteins change in favor of many viral agents. Activation of the human body cell replication mechanism is required for viral genome replication. It has been shown to alter the regulatory function of p53 and pRB in response to the action of several viral proteins. The SV40 virus inactivates it by binding to the major T antigen, the adenovirus E1B protein, and the human papilloma virus E6 protein p53. Similarly, SV40 major T antigen, adenovirus E1A protein, and human papilloma virus E7 protein form a complex with insufficiently phosphorylated pRB, leading to inactivation of pRB and cell immortalization. Highly altered tumor virus strains encode proteins that bind and inactivate p53 and pRB. When growth control is impaired as a result of inhibition of pRB in normal cells, apoptotic death occurs by the normal p53 side. Loss of regulatory activity of p53 and pRB, stable activation of E2F stimulates uncontrolled cell proliferation, leading to neoplastic cell growth. The nature and high frequency of p53 and pRB mutations in primary tumors make them prototypes of tumor suppressor genes. In

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

addition, the detection of mutations in the p53 and pRB genes and changes in the expression of their coded products have clinical prognostic significance in the identification of specific types of cancer⁷⁶. Mutant gene p53 and Ki 67 hyperexpression in osteosarcoma cells was found to alter treatment efficacy in 37.4% of patients⁵⁶.

Thus, cell growth and its management are complex biological processes that occur through site-specific binding of factors belonging to relevant groups to each other. These factors, which have a well-defined trajectory of impact, are coded products of the cell genome. In this sense, the initiating factors of molecular mechanisms activated in a cancer cell are structural changes in the DNA matrix or functional defects in the epigenome.

Signal transduction cascades

The composition, structure, properties, and events of cells are related to the molecules and the chemical reactions that take place between them. Due to the coordination of these biochemical processes that take place, the integrity of the organism is maintained. The same integration system is based on intercellular and intracellular signal transduction. Signal transduction is any process that transmits one type of signal or stimulus in a cell to another. Intracellular signal transduction is a chain of reactions carried out sequentially by enzymes, the primary effector proteins being activated after receptor stimulation, and some by secondary messengers. The duration of such processes usually occurs at high speeds: milliseconds for ion channels, minutes for protein kinases⁴⁴. As the number and activity of protein molecules and other substances involved in signal transduction gradually increase, the primary effector increases as it moves away from the signal. In the same way, a relatively weak effect on cell receptors can also trigger a significant response. There are several types of intracellular signaling cascades (PI-3-Kinase/Act, JAK-STAT, NF-kB, heterotrimer G-proteins, Ras-MAPK/ERK, Wnt, Hedgehog, Fas, TREM2) as a result of the stimulus factor activates, then transmits the cascade signals to the genetic apparatus in the nucleus. Another mechanism that causes the acceleration of the process of carcinogenesis is the hyperactivation of these signal-transmitting cascades³. Nuclear signals from activated cascades cause abnormal changes in the genome or epigenome, which in turn negatively affects cell reproduction and leads to the development of cancer cells. The reception of primary signals by the cell is ensured by ultra-correct binding of special proteins - receptors with ligands. Cell receptors are divided into the following types: membrane (tyrosine kinase, G-protein, ion channels), cytoplasm and nuclear receptors^{9,52}. Once the ligand binds to the membrane receptor, it transmits the information to the

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

protein components of the membrane, which provide signal generation across the cascade². Membrane proteins of the signal transduction cascade are divided into: receptor-bound transduction-protein, transduction-protein-associated catalytic domain-containing proteins that activate secondary effectors that transmit information into the cell^{4,8}.

Scientists from the Department of Molecular and Cellular Biology at Baylor College of Medicine in Houston, United States, studied the effects of transcriptome and ChIP-Seq data on transcriptional regulation of cell signaling pathways. The vast body of accurate data and hypotheses obtained led to the generation of the Signaling Pathways Project (SPP). According to him, cell signaling pathways consist of points that are classified into three major categories (receptors, enzymes, transcription factors) and small biologically active molecules (bioactive small molecules, BSMs) that modulate their activity. Based on the SPP knowledge base, a range of signal path modules and bionam samples was developed, cell receptors were classified according to the International Pharmacological Union (IUPHAR), enzymes International Union of Biochemistry and Molecular Biology (IUBMB) and transcription factors TFCclass 52. In addition, the classification of biological tissues and cell lines according to the physiological system of their organs and origin helps to understand the laws of tissue-specific transcriptional regulation⁵². In ChIP-Seq experiments and integrated transcriptomes (expression sequence and RNA-Seq), the interaction of signal path nodes in transcription regulation can be determined by sequential placement (signature consensus) of parameters based on target genome promoter employment and differential expression. Metabolic signals with a biological terminal point connect receptors, enzymes, and transcription factors through a series of interrelated interactions. These three categories of the signal pathway act as convergence and integration points, ensuring divergence and distribution on the one hand, and an appropriate response of any cell to afferent metabolic signals on the other. The intracellular signaling cascade activated under the influence of extracellular mitogenic factors has a motivational vector consisting of sequential activation of kinase proteins.

Ras/Raf/MEK/ERK signal cascade

Mitogen-activated protein kinase (MAPK) cascades are one of the main signaling pathways that control a wide range of biological processes, including cell proliferation, differentiation, apoptosis, and stress reactions^{12,19,23,24}. Extracellular signal-regulated kinase 1/2 (extracellular signal-regulated kinase, ERK) belongs to the MAPK family and is the main effector in cascade signals²⁵. These cascades transmit signals by sequential activation of three to five protein kinase

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

layers known as MAPK kinase kinase kinase (MAP4K), MAPK kinase kinase (MAP3K), MAPK kinase (MAPKK), MAPK, and MAPK-activated protein kinases (MAPKAPK)³⁷. The first three central layers are considered as the main block, while the last two layers appear in some cascades, which may vary according to cells and stimuli. Based on the components in the MAPK layer, four MARK cascades are distinguished: ERK 1/2, c-Jun N-terminal kinase (JNK), p38 MAPK and ERK5. The ERK cascade contains several kinases in the MAP3K layer (mainly Rafs), including the Ras / Raf / MEK1 / 2 MAPKK layer, the ERK 1/2 MAPK layer, and several MAPKAPKs in the next layer (ribosomal s6 kinases, interacting with MAP kinases), affecting serine / threonine-protein kinases, mitogen and stress-activated protein kinases, and cytosol phospholipase A2)³⁹. ERK cascades are highly regulated cascades that involve cell proliferation and differentiation. These regulatory factors affect bispecific phosphatases, carcass proteins (cascade-forming), signal duration and intensity, and dynamic subcellular localization of cascade components¹⁷. Excessive activation of proteins and kinases located in the upper layer of the ERK pathway has been shown to cause cancer, inflammation, neurological and other diseases^{18,29,66,80}. Dysfunction in the Ras- ERK pathway is a trigger factor in the development of many cancers, with mutations in the activating driver genes of this pathway being the most common oncogenic factor in all cancers³³. In cancer, the different components in the cascade are highly variable. According to Maik-Rachline G, Hacoheh-Lev-Ran A, Seger R. driver mutations in Ras (mainly K-ras) are the most common mutations in cancer, occurring in ~ 30% of cancers and ~ 10% of cancer patients⁴⁴. Raf mutations (particularly B-Raf) have been identified in ~ 8% of cancers^{63,64}. ERK is a type of serine / threonine protein kinase, a protein that transmits mitogenic signals. ERK is usually located in the cytoplasm, enters the nucleus after activation, and regulates the activity of transcription factors and gene expression. Analysis of artificial cloning and sequencing showed that the ERK family consists of: ERK 1, 2, 3, 4,5 and 6⁵⁵. Although ERK 1 and ERK 2 are two important members of the MAPK / ERK pathway, ERK 5 is also highly active in transcription management. The S-terminal of ERK 5 includes the nuclear localization signal (NLS), two proline-rich sites, and the transcription activation domain (TAD). This structural difference allows the active ERK5 to spontaneously phosphorylate its C-terminal TAD, a unique feature of ERK5 that directly controls gene transcription. In the non-phosphorylated state, ERK 5 is in an inactive conformation and its N- and C-terminal domains are bound to each other in the cytoplasm. Activation of MEK5 induces an open

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

conformation of ERK5, opens NLS, softens self-inhibition, and induces nuclear translocation of ERK5^{58,59,75}.

Many stimulants, such as growth factors, cytokines, viruses, G-protein-bound receptor ligands, and oncogenes, activate the ERK pathway¹⁷. The main molecules in the ERK/MAPK signaling pathway mainly include Ras small G proteins and the lower layer Raf kinase, MEK1 / 2 and ERK1 / 2. Ras is the most conservative product of the ras gene family encoded by *Ha-ras*, *Hi-ras*, and *N-ras* oncogenes. Raf kinase is a derivative of *raf* oncogenes. MEK1 and MEK2 are rare bispecific kinases that activate ERK by phosphorylation of two regulatory sites Tyr 204/187 (tyrosine) and Thr 202/185 (threonine)¹⁰. Ras is a small G protein located at the apex of the Raf-MEK-ERK pathway that is a product of *ras* oncogenes (retrovirus-associated DNA sequences). It has a conformation associated with active GTP (guanosine triphosphate) and a conformation associated with inactive GDP (guanosine diphosphate)⁴⁹. The protein acts as a molecular binder by switching between two conformations to regulate signal transduction. Ras is activated by many stimulatory factors, such as epidermal growth factor (EGF), tumor necrosis factor, protein kinase activators C (PKC), and members of the Src family. After the extracellular signal binds to the receptor, the protein 2 (Grb2) bound to the growth factor receptor binds to the activated receptor and interacts with the proline-rich tandem site at the S-terminal of SOS (Son of sevenless) to form the receptor-Grb2-SOS complex^{4,17}. Binding of the SOS to the phosphorylated Tyr site in the receptor or receptor substrate protein results in translocation of the cytoplasmic SOS to the membrane, resulting in a high SOS concentration around the Ras. SOS and Ras-GDP stimulate the replacement of GDP in Ras with GTP and thus activate Ras to start the Ras pathway^{42,43}. Raf (rapidly accelerated fibrosarcoma) protein kinase is a protein composed of 648 amino acids encoded by the *raf* gene located on human 3rd chromosome and has a molecular weight of 40–75 kDa ge. Serine/threonine exhibits protein kinase activity after binding to Raf Ras. Its molecular structure includes three conservative regions: Conserved region (CR) 1 (located in amino acids 61-194), CR2 (located in amino acids 254-299) and CR3 (located in amino acids 335-627). The CR1 cysteine-rich zinc located in the amino-terminal has a zinc-like structure and a structure similar to the ligand binding site of PKC. CR1 is the main site of activated Ras binding to Raf-1 protein kinase. CR2 is present near the amino terminal and contains many serine and threonine residues⁶². CR3, located at the carboxyl terminal, is the catalytic functional domain of Raf-1 protein kinase. The family of Raf kinases is divided into three subtypes: Raf-1, A-Raf, and B-Raf. Raf kinases can be activated in the


[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

following ways: 1) Raf interacts with Ras on the inside of the cell membrane; 2) Dimerization of Raf protein; 3) phosphorylation and dephosphorylation of various sites; 4) Separation by Raf kinase inhibitor; 5) Binding to Ras kinase inhibitors^{58,59}. Raf-1 Ras/Raf/MEK/ERK plays an important role in cell proliferation signal pathway. In the pathway of Ras/Raf/MEK/ERK signal transduction and activation from the Raf cytoplasm to the inside of the cell membrane, Ras is used as an active protein in the upper layer and from two sites, namely the Ras-binding domain and cysteine-rich domain at the N-terminal of Raf-1. Activated Raf-1 continues to activate MEK and MAPK in the lower layer and eventually regulates gene expression by controlling the activity of transcriptional regulatory factors by delivering cell proliferation and differentiation signals to the nucleus^{30,72}. Among the subtypes of Raf kinases, A-Raf shows the weakest kinase activity, while B-Raf shows the strongest activity. Among the three subtypes, the highest 90% of B-Raf mutations are seen in melanoma^{13,14,68}. After Raf activation, the S-terminal interacts with the catalytic domain MEK (MAPK/ERK kinase, MARK-extracellular regulated kinase) and the catalytic VIII subsystem is phosphorylated in the cool residue and activates MEK. Two subtypes of MEK, MEK1 and MEK2, have molecular weights of 44 and 45 kDa, respectively^{46,70}. MEK is a unique and bilaterally specific kinase that activates ERK by phosphorylation of Tyr and Thr regulator sites⁷⁵. The specific phosphorylation activity of MEK Tyr and Thr is of significant physiological importance because ERK occupies a central position in the signaling pathway and any errors in activation can have a profound effect on cellular processes. This two-way recognition and activation mechanism transmits the signal very accurately and prevents errors in ERK activation^{31,65}. MEK not only activates ERK, but also establishes ERK in the cytoplasm. When the signal is inactive, ERK is localized in the cytoplasm. After the signal stimulates the phosphorylation and dimerization of ERK, the activated ERKs are transferred to the nucleus, promoting the phosphorylation of cytoplasmic target proteins or regulating the activity of other protein kinases. Various stimuli such as cytokines, viruses, G-protein-bound receptor ligands, and oncogenes play a regulatory role by activating the ERK/MAPK signaling pathway^{77,82}. The ERK/MAPK signal pathway can be activated in the following ways: 1) Ca²⁺ channel activation; 2) Activation of Ras tyrosine kinase receptors; 3) PKC-mediated activation; 4) Activation of receptors bound to G proteins^{39,41}. ERK1/2 is located in the cytoplasm in unstimulated cells. Once activated, ERK1/2 passes into the nucleus and regulates the activity of various transcription factors through phosphorylation, thereby regulating cell metabolism and biological functions. Microtubule-associated protein (MAP) 1 is

[SJIF 2020: 6.224](#)
[IFS 2020 4.085](#)

involved in regulating cell morphology and cytoskeletal redistribution through the phosphorylation of cytoskeletal components such as MAP2 and MAP4. Nuclear transcription factors such as protooncogen c-Fos, protooncogen c-Jun, ETS domain-protective protein Elk-1, protooncogen c-Myc, and cyclic AMP-dependent transcription factor ATF2 are phosphorylated in the nucleus^{35,38} (Figure 3). Cytoplasmic ERK1/2 can phosphorylate a number of other protein kinases in the upper part of the ERK pathway, such as SOS, Raf-1, and MEK, by negative feedback. Activation of ERK/MAPK signal pathways can activate other cellular signaling pathways. Vascular endothelial growth factor (VEGF), platelet-derived growth factor, and epidermal growth factor (EGF) activate the ERK/MAPK pathway by acting on tyrosine kinase receptors. When activated ERK enters the nucleus and binds to transcription factors that cause gene expression in response to extracellular stimuli, it can regulate cell proliferation, differentiation, apoptosis, and transcription^{67,74}. According to Rubinfeld Hadara, Seger Rony, the ERK/MAPK signaling pathway is not only involved in the management of biological functions such as cell proliferation, cell differentiation, cell cycle regulation, cell apoptosis, and tissue formation, but is also associated with tumor development. High ERK expression is detected in ovarian, colon, breast, and lung cancers^{61,69}.



[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

Figure 3. Ras/Raf/MEK/ ERK signal pathway. GF-growth factors; RTK-tyrosine kinase receptors; GRB2 is a protein binding to growth factor receptors 2; SOS - Son of sevenless

Continuous activation of the ERK/MAPK signal pathway may promote the transformation of normal cells into tumor cells, inhibition of the ERK/MAPK signal pathway may inhibit the growth of transformed cells^{78,79}. Therefore, activation of the ERK/MAPK signaling pathway may be closely associated with tumor emergence and development⁴⁵. Unrestricted cell proliferation, differentiation, and lack of apoptosis are important biological features of tumors. Activation of the ERK/MAPK signal pathway promotes proliferation and has an anti-apoptotic effect. Matrix metalloproteinases (MMPs) are proteolytic enzymes that hydrolyze the extracellular matrix, one of the most important processes in cancer cell invasion and metastasis²⁶. Excessive expression of MMPs is beneficial for invasive tumor formation and metastasis, while inhibition of MMP expression has the opposite effect. Activation of the ERK/MAPK signal pathway may enhance tumor invasion and metastasis by regulating MMP expression, whereas inhibition of this signal pathway may reduce tumor invasion and metastasis^{7,26}. Cell deformation and migration that occur during tumor metastasis are associated with microfilament-bound protein expression in the cytoskeleton. Studies have shown that hepatocyte growth factor (HGF) enhances migration by activating the ERK/MAPK signaling pathway, thereby promoting invasion and metastasis^{11,67}. Blockade of the ERK/MAPK signaling pathway stops tumor invasion and metastasis by inhibiting HGF and other extracellular signals that promote cell movement⁶⁷. In the absence of tumor blood vessels, its tissue rarely exceeds 2 mm³³⁴. VEGF is an important proangiogenic factor and the most potent provascular endothelial growth cytokine that enhances cancer cell division and vascular construction, increases microvascular permeability, and activates endothelial cell migration⁶⁷. ERK/ MAPK signaling pathways may enhance VEGF transcription, increase VEGF expression in tumor cells, and activate vascular formation. Interleukin (IL) -8 and VEGF together are manifested in various tumors and may promote tumor angiogenesis, growth, and metastasis. ERK1/2 can be used as an alternative pathway causing IL-8 and VEGF expression. Inhibition of the ERK/MAPK signal pathway may be the basis for inhibition of tumor angiogenesis. In addition, hypoxia-inducing VEGF can inhibit apoptosis by activating the ERK/MAPK signaling pathway. The target layer in the lower layer of ERK/MAPK is ribosomal S6 kinase 1 (p70S6K1), an important regulator of cell cycle development and proliferation. Studies show that a vector-based microRNA against p70S6K1 inhibits p70S6K1 activity in ovarian cancer cells and reduces VEGF protein expression⁶.

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

Conclusion

Through an in-depth analysis of the molecular mechanism of carcinogenesis, it is possible to obtain information about the many biological processes in it that determine the phenotype of cancer cells. Despite the rapid development of medicine today, these cardinal processes only allow to identify the changes around them, which makes it difficult to treat the disease. In order to penetrate the central block of biological processes occurring in cancer cells, it is necessary to identify and in-depth analysis of the pathways leading to it. For example, stable mutations in the genome or defects in the epigenome lead to abnormal cell proliferation, underlying DNA chain damage or dysfunction in the control system, the causes of which are various types of carcinogenic factors, both known and unknown. However, we do not have a fully integrated knowledge of the exact direction of these causal vectors and the complex chemical reactions that take place between them in an interconnected and consistent, time sequence. However, by breaking this chain of reactions, new opportunities can be created in the prevention and treatment of this disease. It is known from chemistry that the rate of chemical reactions depends on the concentration and nature of the substances involved in the reaction, the catalysts (enzymes). The high concentration of substrates required for chemical reactions makes cancer cells more reliable than normal cells due to their high rate of active migration, and enzymatic potency. Under the influence of these highly concentrated substances and hyperactive catalytic enzymes lead to the formation of biomolecules of various natures, activating the chain processes between them. The amount of proteins in each segment and the degree of activity of their catalytic domains are also of great importance in signal transmission along the cell cascade pathways. The Ras/Raf/MEK/ERK signaling pathway is also a complex network of sequentially activated proteins that play a major role in the onset and development of cancer. Due to the sequential activation of protein kinases in the Ras/Raf/MEK/ERK cascade pathway, the signals are transduced from the plasma membrane along the genome direction and become a potent effector that affects cell activity. Phosphorylation using protein kinases is one of the main biological processes that control the posttranslational modification of proteins, determining the way of life of cells. Proteins and molecular factors from other groups are also actively involved in the posttranslational control of proteins synthesized through gene expression, and play a role in the complete expression of their function. Due to mutations in the driver genes at the corresponding loci of the chromosome, these processes become overactive and disrupted in cancer cells, resulting in the response to extracellular signals being so

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

intense. While the period from mutation of these genes to the initial clinical stage of cancer is considered an indolent period of carcinogenesis, it leads to reliable protection of cancer cells against the background of deescalation of the human immune system at the expense of enormous rate of division. In the treatment of cancer, it is only through the disintegration or decontamination of elements of this pathogenetic framework that it is possible to maintain healthy cells and to abandon aggressive treatments. Innovative technologies can provide new ways to treat cancer by creating a realistic picture of integrated biological data and ensuring its effective implementation when needed.

Based on clinical observations during the pandemic period, coronavirus infection can occur in different severity in everyone, depending on the state of the body's immunity and susceptibility, the presence of other causative factors, the level of comorbidity index. In this sense, the origin of cancer is also related to the influence of biological or non-biological agents that integrate with the human genome, or can change the biological cycle of the cell to its side. However, in the local development of cancer, the most favorable, weakly protected or high carcinogenic load is selected.

[SJIF 2020: 6.224](#)
[IFS 2020 4.085](#)

References

1. Abdukhakimov AN. Enigmatic cancer. Navruz. 2017. 112.
2. Andrew M. Kidger, James Siphthorp, Simon J. Cook. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. *Pharmacology & Therapeutics*. 2018;Volume 187: 45-60.
3. Antonio MG, Ester S, Lucia F, Vito V, Martina S, Paolo AA. MEK Inhibitors in the treatment of metastatic melanoma and solid tumors. *Am. J. Clin. Dermatol*. 2017.
4. Bandaru P, Kondo Y and Kuriyan J. The interdependent activation of son-of-sevenless and ras. *Cold Spring Harb Perspect Med*. 2019;9: pii: a031534.
5. Becnel, L. B. et al. Discovering relationships between nuclear receptor signaling pathways, genes, and tissues in Transcriptomine. *Sci Signal*. 2017;10.
6. Bian CX, Shi Z, Meng Q, Jiang Y, Liu LZ and Jiang BH. P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression. *Biochem Biophys Res Commun*. 2010;398: 395-399.
7. Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, Rusu A, Irimie A, Atanasov AG, Slaby O, et al. A comprehensive review on MAPK: A promising therapeutic target in cancer. *Cancers (Basel)*. 2019;11: pii: E1618.
8. Buffet C, Hecale-Perlemoine K, Bricaire L, Dumont F, Baudry C, Tissier F, Bertherat J, Cochand-Priollet B, Raffin-Sanson ML, Cormier F, et al. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers. *PLoS ONE*. 2017;12: e0184861.
9. Bustelo XR. Rho GTPases in cancer: known facts, open questions, and therapeutic challenges. *Biochemical Society Transactions*. 2018; 46: 741–760.
10. Cassier E, Gallay N, Bourquard T, Claeysen S, Bockaert J, Crepieux P, Poupon A, Reiter E, Marin P & Vandermoere F. Phosphorylation of beta-arrestin2 at Thr(383) by MEK underlies beta-arrestin-dependent activation of Erk1/2 by GPCRs. *eLife*. 2017;6: e23777.
11. Caunt, C., Sale, M., Smith, P. et al. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. *Nat Rev Cancer*. 2015;15: 577–592.
12. Cheng, Y.; Tian, H. Current Development Status of MEK Inhibitors. *Molecules*. 2017;22: 1551.

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

13. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. *J Clin Oncol.* 2012;30: 2522-2529.
14. Dankner M, Rose AAN, Rajkumar S, Siegel PM & Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. *Oncogene.* 2018;37: 3183–3199.
15. David E. Malarkey , Mark Hoenerhoff , Robert R. Maronpot. *Carcinogenesis: Mechanisms and Manifestations.* Haschek and Rousseaux's Handbook of Toxicologic Pathology, Third Edition. 2013; 107–146.
16. DeCaprio JA, et al. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. *Cell.* 1989;58: 1085–95.
17. Dohlman HG and Campbell SL. Regulation of large and small G proteins by ubiquitination. *J Biol Chem.* 2019;294: 18613-18623.
18. Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2017;18: 435–445.
19. Eblen ST. Extracellular-regulated kinases: Signaling from ras to ERK substrates to control biological outcomes. *Adv Cancer Res.* 2018;138: 99-142.
20. El-Deiry WS. p21(WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy. *Cancer Res.* 2016;76: 5189–91.
21. Ezkurdia I., Juan D., Rodriguez J. M. et al. Multiple evidence strands suggest that there may be as few as 19,000 human protein-coding genes. *Human Molecular Genetics.* 2014; 23 (22): 5866–5878.
22. Foster SS, De S, Johnson LK, Petrini JH, Stracker TH. Cell cycle- and DNA repair pathway-specific effects of apoptosis on tumor suppression. *Proc Natl Acad Sci USA.* 2012;109: 9953–8.
23. Frodyma D, Neilsen B, Costanzo-Garvey D, Fisher K & Lewis R. Coordinating ERK signaling via the molecular scaffold kinase suppressor of ras. *F1000Research.* 2017;6: 1621.
24. García-Gómez R, Bustelo XR and Crespo P. Protein-protein interactions: Emerging oncotargets in the RAS-ERK pathway. *Trends Cancer.* 2018;4: 616-633.

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

25. Geenen JJJ, Schellens JHM. Molecular pathways: targeting the protein kinase Wee1 in cancer. *Clin Cancer Res.* 2017;23: 4540–4.
26. Gialeli C, Theocharis AD and Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. *FEBS J.* 2011;278: 16-27.
27. Gopinathan L, Ratnacaram CK, Kaldis P. Established and novel Cdk/cyclin complexes regulating the cell cycle and development. *Results Probl Cell Differ.* 2011;53: 365–89.
28. Handbook of Oncology. Edited by Academician of the Russian Academy of Medical Sciences N.N. Trapeznikov and Professor I.V. Poddubnaya. Moscow: Kappa, 1996.
29. Herrero A, Pinto A, Colon-Bolea P, Casar B, Jones M, Agudo-Ibanez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizan EM, et al. Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS-ERK pathway oncogenes. *Cancer Cell.* 2015;28: 170–182.
30. Holderfield M, Deuker MM, McCormick F and McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. *Nat Rev Cancer.* 2014;14: 455-467.
31. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. *J Clin Oncol.* 2017;35: 2624-2630.
32. Kato S, et al. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. *Cell Cycle.* 2015;14: 1252–9.
33. Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F and Hong DS. Targeting TRK family proteins in cancer. *Pharmacol Ther.* 2017;173: 58-66.
34. Krishna Priya S, Nagare RP, Sneha VS, Sidhanth C, Bindhya S, Manasa P and Ganesan TS. Tumour angiogenesis-Origin of blood vessels. *Int J Cancer.* 2016;139: 729-735.
35. Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, et al. EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC. *Cancer Discovery.* 2019;9: 264–281.
36. Lauren Pecorino. *Molecular Biology of Cancer Mechanisms, Targets, and Therapeutics.* Third edition. Oxford University Press, 2012.
37. Lavoie H & Therrien M. Regulation of RAF protein kinases in ERK signalling. *Nature Reviews: Molecular Cell Biology.* 2015;16: 281–298.

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

38. Lavoie H, Sahmi M, Maisonneuve P, Marullo SA, Thevakumaran N, Jin T, Kurinov I, Sicheri F & Therrien M. MEK drives BRAF activation through allosteric control of KSR proteins. *Nature*. 2018;554: 549–553.
39. Lawrence MC, Jivan A, Shao C, Duan L, Goad D, Zaganjor E, Osborne J, McGlynn K, Stippec S, Earnest S, et al. The roles of MAPKs in disease. *Cell Res*. 2008;18: 436-442.
40. Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. *Development*. 2013;140: 3079–93.
41. Lu P, Chen J, Yan L, Yang L, Zhang L, Dai J, Hao Z, Bai T, Xi Y, Li Y, et al. RasGRF2 promotes migration and invasion of colorectal cancer cells by modulating expression of MMP9 through Src/Akt/ NF-kappaB pathway. *Cancer Biology and Therapy*. 2018;20: 435–443.
42. Ma Y, Xu Y and Li L. SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling. *Exp Ther Med*. 2018;16: 3195-3201.
43. Mahapatra DK, Asati V, Bharti SK. MEK inhibitors in oncology: A patent review (2015–Present). *Expert Opin. Ther. Pat*. 2017.
44. Maik-Rachline G, Hacoheh-Lev-Ran A and Seger R. Nuclear ERK: Mechanism of translocation, substrates, and role in cancer. *Int J Mol Sci*. 2019;20: pii: E1194.
45. Mandal R, Becker S & Strebhardt K. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. *Oncogene*. 2016;35: 2547–2561.
46. Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S. The protein kinase complement of the human genome. *Science*. 2002;298: 1912-1934.
47. Mazouzi A, Velimezi G, Loizou JI. DNA replication stress: causes, resolution and disease. *Exp Cell Res*. 2014;329: 85–93.
48. Mesplede T, et al. p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. *J Virol*. 2012;86: 94–107.
49. Muñoz-Maldonado C, Zimmer Y and Medová M. A comparative analysis of individual RAS mutations in cancer biology. *Front Oncol*. 2019;9: 1088.
50. Muta Y, Matsuda M and Imajo M. Divergent dynamics and functions of ERK MAP kinase signaling in development, homeostasis and cancer: Lessons from fluorescent bioimaging. *Cancers (Basel)*. 2019;11: pii: E513.
51. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. *Nat Rev Mol Cell Biol*. 2001;2: 21–32.

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

52. Ochsner, S.A., Abraham, D., Martin, K. et al. The Signaling Pathways Project, an integrated ‘omics knowledgebase for mammalian cellular signaling pathways. *Sci Data*. 2019;6: 252.
53. Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. *Nat Rev Cancer*. 2017;17: 93–115.
54. Pardal, R., Molofsky, A.V., He, S., Morrison, S.J. Stem cell self-renewal and cancer cell proliferation are regulated by common networks that balance the activation of proto-oncogenes and tumor suppressors. *Cold Spring Harb. Symp. Quant. Biol.* 2005;70: 177–185.
55. Plotnikov A, Zehorai E, Procaccia S and Seger R. The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. *Biochim Biophys Acta*. 2011;1813: 1619-1633.
56. Polatova D.S. The state of molecular biological markers in osteosarcoma. *Annals of Oncology*. 2019;IX138, Volume 30.
57. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. *Curr Opin Cell Biol*. 2009;21: 245–55.
58. Roskoski R Jr. ERK1/2 MAP kinases: Structure, function, and regulation. *Pharmacol Res*. 2012;66: 105-143.
59. Roskoski R Jr. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. *Pharmacol Res*. 2019;142: 151-168.
60. Rubin SM. Deciphering the retinoblastoma protein phosphorylation code. *Trends Biochem Sci*. 2013;38: 12–9.
61. Rubinfeld H and Seger R. The ERK cascade: A prototype of MAPK signaling. *Mol Biotechnol*. 2005;31: 151-174.
62. Rukhlenko OS, Khorsand F, Krstic A, Rozanc J, Alexopoulos LG, Rauch N, Erickson KE, Hlavacek WS, Posner RG, Gómez-Coca S, et al. Dissecting RAF inhibitor resistance by structure-based modeling reveals ways to overcome oncogenic RAS signaling. *Cell Syst*. 2018;7: 161-179.e14.
63. Sanchez JN, Wang T and Cohen MS. BRAF and MEK inhibitors: Use and resistance in BRAF-mutated cancers. *Drugs*. 2018;78: 549-566.
64. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafeinia S, et al. Oncogenic signaling pathways in the cancer genome atlas. *Cell*. 2018;173: 321-337.e10.

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

65. Seternes OM, Kidger AM and Keyse SM. Dual-specificity MAP kinase phosphatases in health and disease. *Biochim Biophys Acta Mol Cell Res.* 2019;1866: 124-143.
66. Simanshu DK, Nissley DV and McCormick F. RAS proteins and their regulators in human disease. *Cell.* 2017;170: 17-33.
67. Song M and Finley SD. Mechanistic insight into activation of MAPK signaling by pro-angiogenic factors. *BMC Syst Biol.* 2018;12: 145.
68. Sun W, Kesavan K, Schaefer BC, Garrington TP, Ware M, Johnson NL, Gelfand EW and Johnson GL. MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. *J Biol Chem.* 2001;276: 5093-5100.
69. Tang Q, Wu J, Zheng F, Hann SS and Chen Y. Emodin increases expression of insulin-like growth factor binding protein 1 through activation of MEK/ERK/AMPK α and interaction of PPAR γ and Sp1 in lung cancer. *Cell Physiol Biochem.* 2017;41: 339-357.
70. Terrell EM and Morrison DK. Ras-mediated activation of the raf family kinases. *Cold Spring Harb Perspect Med.* 2019;9: pii: a033746.
71. Thomas D. Pollard, William C. Earnshaw, Jennifer Lippincott-Schwartz, Graham T. Johnson. *Cell biology.* Third edition. Philadelphia, PA : Elsevier, 2017.
72. Vandamme D, Herrero A, Al-Mulla F and Kolch W. Regulation of the MAPK pathway by raf kinase inhibitory protein. *Crit Rev Oncog.* 2014;19: 405-415.
73. Visconti R, Della Monica R, Grieco D. Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. *J Exp Clin Cancer Res.* 2016;35: 153.
74. Vladimirova L. Yu. The use of MEK inhibitors in oncology: results and prospects. *Success of modern natural science.* 2015;3: 18–30.
75. Wainstein E and Seger R. The dynamic subcellular localization of ERK: Mechanisms of translocation and role in various organelles. *Curr Opin Cell Biol.* 2016;39: 15-20.
76. Wallace MD, Southard TL, Schimenti KJ, Schimenti JC. Role of DNA damage response pathways in preventing carcinogenesis caused by intrinsic replication stress. *Oncogene.* 2014;33: 3688–95.
77. Wang, C., Chen, Z., Nie, L. et al. Extracellular signal-regulated kinases associate with and phosphorylate DHPS to promote cell proliferation. *Oncogenesis.* 2020;9: 85.
78. Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjöblom, T., Leary, R.J., Shen, D., Boca, S.M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso, Z., Ustyanksky, V., Nikolskaya, T., Nikolsky,

[SJIF 2020: 6.224](#)

[IFS 2020 4.085](#)

Y., Karchin, R., Wilson, P.A., Kaminker, J.S., Zhang, Z., Croshaw, R., Willis, J., Dawson, D., Shipitsin, M., Willson, J.K., Sukumar, S., Polyak, K., Park, B.H., Pethiyagoda, C.L., Pant, P.V., Ballinger, D.G., Sparks, A.B., Hartigan, J., Smith, D.R., Suh, E., Papadopoulos, N., Buckhaults, P., Markowitz, S.D., Parmigiani, G., Kinzler, K.W., Velculescu, V.E., Vogelstein, B. The genomic landscapes of human breast and colorectal cancers. *Science*. 2007;318: 1108–1113.

79. Yang S and Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. *Oncol Lett*. 2017;13:1041-1047.

80. Yan-Jun Guo, Wei-Wei Pan, Sheng-Bing Liu, Zhong-Fei Shen, Ying Xu and Ling-Ling Hu. ERK/MAPK signalling pathway and tumorigenesis (Review). *Experimental and Therapeutic Medicine*. 2020;19: 1997-2007.

81. Yoo, M., Hatfield, D.L. The cancer stem cell theory: Is it correct? *Mol. Cells*. 2008;26: 514–516.

82. Zhou B, Der CJ and Cox AD. The role of wild type RAS isoforms in cancer. *Semin Cell Dev Biol*. 2016;58: 60-69.